Endothelial Dysfunction for Prognosis In Patients With preeClampSia

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorHeidelberg University

About this trial

Preeclampsia is a pregnancy-specific hypertensive disorder and can progress rapidly to severe adverse outcomes affecting both the mother and the fetus. Endothelial and microcirculatory dysfunction mediate systemic preeclampsia-related organ dysfunctions. Changes in endothelial and vascular function in preeclampsia have been demonstrated through reduced flow-mediated vasodilation as a result of reduced availability of nitric oxide, which potentially persists up to several years postpartum. Hyperspectral imaging is a new innovative technology that allows to assess the peripheral microcirculation and perfusion non-invasively and contactless, but has never been evaluated in the context of preeclampsia before.

This EPICS project (Endothelial dysfunction for Prognosis In patients with preeClampSia) is a prospective observational study and aims to investigate hyperspectral imaging as a new potential diagnostic and prognostic marker in preeclampsia.

Eligibility criteria

Qualifiers

singleton pregnancies

Age ≥ 18 years

Patient's ability to provide consent

written informed consent

Disqualifiers

Lack of consent

Language barrier

Dark to very dark skin type

Severe fetal chromosomal/genetic/structural anomalies

Trial design

Treatments tested in this trial

  • Hyperspectral imaging
  • Further markers of endothelial dysfunction

Treatment groups

385 Participants
are divided into 4 treatment groups

Sponsors and collaborators